Total trials
538
Active
162
Phase 3
25
Total enrollment
524,064
Pipeline matrix
Showing 40 of 114 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Amoxicillin | — | — | — | — | — | 2 | |
| Human Papilloma Virus vaccine | — | — | — | — | — | 1 | |
| Ampicillin for | — | — | — | — | — | 1 | |
| Ceftriaxone for | — | — | — | — | — | 1 | |
| Ampicillin / Sulbactam | — | — | — | — | — | 1 | |
| Amoxicillin-clavulanate | — | — | — | — | — | 1 | |
| Clindamycin | — | — | — | — | — | 1 | |
| Cefprozil | — | — | — | — | — | 1 | |
| Levofloxacin | — | — | — | — | — | 1 | |
| Insulin | — | — | — | — | — | 1 | |
| GLP-1 agonists | — | — | — | — | — | 1 | |
| Nifedipine ER | — | — | — | — | 2 | ||
| Labetalol, Nifedipine | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | 14 | |||
| Dexamethasone | — | — | — | — | 4 | ||
| Isatuximab | — | — | — | — | — | 3 | |
| Doxorubicin | — | — | — | — | 3 | ||
| Prednisone | — | — | — | — | 4 | ||
| Venetoclax | — | — | — | — | 3 | ||
| Concurrent chemotherapy | — | — | — | — | — | 2 | |
| Chemotherapy | — | — | — | — | 2 | ||
| Tacrolimus | — | — | — | 8 | |||
| Mycophenolate Mofetil | — | — | — | — | 5 | ||
| Pacritinib | — | — | — | — | — | 2 | |
| Abemaciclib | — | — | — | — | 2 | ||
| Imatinib | — | — | — | — | — | 2 | |
| Nilotinib | — | — | — | — | — | 2 | |
| Dasatinib | — | — | — | — | — | 2 | |
| Pomalidomide | — | — | — | — | 2 | ||
| Lenalidomide | — | — | — | — | — | 2 | |
| Paclitaxel | — | — | — | — | — | 2 | |
| Carboplatin | — | — | — | — | — | 2 | |
| Induction Chemotherapy | — | — | — | — | — | 1 | |
| Memantine -Twice Daily or Extended Release | — | — | — | — | — | 1 | |
| Ruxolitinib | — | — | — | — | — | 1 | |
| Fosamprenavir Calcium & Sodium Alginate | — | — | — | — | — | 1 | |
| Single Dose Theophylline | — | — | — | — | — | 1 | |
| Repeat Dose Theophylline | — | — | — | — | — | 1 | |
| mFOLFIRINOX Treatment Regimen | — | — | — | — | — | 1 | |
| Gemcitabine/Nab-paclitaxel Treatment Regimen | — | — | — | — | — | 1 |
74 more active programs hidden
Next readouts
- 2023-12-13
- 2023-12-31
- 2024-02-28
- 2025-02-13
- 2025-03-05
- 2025-05-28
- 2025-06-30
- 2025-08-11
- 2026-03
- 2026-03-31
Top conditions
- Breast Cancer16
- Stroke14
- Multiple Myeloma12
- Cardiovascular Diseases10
- HIV10
- Lymphoma9
- Prostate Cancer8
- Obesity8
Frequently asked questions about Medical College of Wisconsin
- How many clinical trials does Medical College of Wisconsin have on ClinicalTrials.gov?
- Medical College of Wisconsin is listed as the lead sponsor on 538 clinical trials in ClinicalTrials.gov, 162 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Medical College of Wisconsin's trials are in Phase 3?
- 25 of Medical College of Wisconsin's trials are in Phase 3, spread across 114 active drug programs.
- What therapeutic areas does Medical College of Wisconsin focus on?
- Medical College of Wisconsin's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Stroke, Multiple Myeloma, Cardiovascular Diseases, HIV.
- When are Medical College of Wisconsin's next clinical trial readouts?
- Medical College of Wisconsin has 10 upcoming primary-completion readouts tracked here; the soonest is “MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer”, expected around 2023-12-13.